Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine
Ehsan Mostafavi, Sana Eybpoosh, Mohammad Karamouzian, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310302-e2310302
Open Access | Times Cited: 21

Showing 21 citing articles:

Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
Xiaodi Wu, Ke Xu, Ping Zhan, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 14
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Kenneth Lundström
Viruses (2024) Vol. 16, Iss. 2, pp. 203-203
Open Access | Times Cited: 9
Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study
Mona Sadat Larijani, Rahim Sorouri, Sana Eybpoosh, et al.
Pathogens and Disease (2023) Vol. 81
Closed Access | Times Cited: 19
Immunological effectiveness of the booster Soberana Plus vaccine (FINLAY-FR-1A)
K. S. Korsak, Е. В. Воропаев, О. В. Осипкина, et al.
Health and Ecology Issues (2025) Vol. 21, Iss. 4, pp. 26-36
Closed Access
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
Behrokh Farahmand, Mona Sadat Larijani, Fatemeh Fotouhi, et al.
Heliyon (2023) Vol. 9, Iss. 10, pp. e20555-e20555
Open Access | Times Cited: 11
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals
Sana Eybpoosh, Alireza Biglari, Rahim Sorouri, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 11, pp. e1011744-e1011744
Open Access | Times Cited: 11
COVID-19 Vaccines: Where Do We Stand at the End of 2023?
Kenneth Lundström
(2024)
Open Access | Times Cited: 3
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up
Mohammadreza Salehi, Ilad Alavi Darazam, Alireza Nematollahi, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112192-112192
Closed Access | Times Cited: 3
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults
Kusnandi Rusmil, Eddy Fadlyana, Rodman Tarigan Girsang, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 540-540
Open Access | Times Cited: 2
Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran
Mona Sadat Larijani, Alireza Biglari, Rahim Sorouri, et al.
Deleted Journal (2024) Vol. 28, Iss. 1, pp. 1-7
Open Access | Times Cited: 1
Accelerate vaccine development using seamless phase 2/3 trial designs
Jiaying Yang, Guochun Li, Ying Yuan
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 523-534
Open Access | Times Cited: 1
Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects
Delaram Doroud, Mona Sadat Larijani, Alireza Biglari, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Comparing the Efficacy and Adverse Events of Available COVID-19 Vaccines Through Randomized Controlled Trials: Updated Systematic Review and Network Meta-analysis
Shima Hossaini, Fariba Keramat, Zahra Cheraghi, et al.
Journal of Research in Health Sciences (2023) Vol. 23, Iss. 4, pp. e00593-e00593
Open Access | Times Cited: 3
A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran
Mahan Ghafari, Sepanta Hosseinpour, Mohammad Saeid Rezaee‐Zavareh, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 2
Iran’s research prioritization: Are we meeting the goals? A study based on clinical trial registry data
Farshid Fakhri, Mohammad Mohammadi, Sana Eybpoosh, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0301414-e0301414
Open Access
Assessment of COVID‐19 Vaccine Impact on Women’s Menstrual Health within an 18‐Month Follow‐Up
Mona Sadat Larijani, Sana Eybpoosh, Delaram Doroud, et al.
Obstetrics and Gynecology International (2024) Vol. 2024, Iss. 1
Open Access
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
Altijana Hromić‐Jahjefendić, Kenneth Lundström, Muhamed Adilović, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 3, pp. 103508-103508
Closed Access | Times Cited: 1
A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths from COVID-19: a counterfactual study on the impact of the delayed vaccination programme in Iran
Mahan Ghafari, Sepanta Hosseinpour, Mohammad Saeid Rezaee‐Zavareh, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Pre-clinical testing of two serologically distinct chimpanzee-origin adenovirus vectors expressing spike of SARS-CoV-2
Arezki Chekaoui, Mikhail Novikov, Zhiquan Xiang, et al.
Research Square (Research Square) (2023)
Open Access
Safety and immunogenicity of COReNAPCIN®, a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial
Mohammadreza Salehi, Ilad Alavi Darazam, Alireza Nematollahi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top